Active Stocks in the Spotlight: Almaden Minerals, Ltd. (NYSE:AAU), Cytori Therapeutics Inc. (NASDAQ:CYTX)

5

Almaden Minerals, Ltd. (NYSE:AAU)

Almaden Minerals is an exploration company specializing in the generation of new mineral projects. The Company focuses primarily on new gold, silver and copper prospects in North America. Almaden Minerals is headquatered in Vancouver, Canada.

Almaden Minerals, Ltd. (NYSE:AAU)’s Financial Overview

Almaden Minerals, Ltd. (NYSE) surged 0% yesterday to close its trading session at $0.61. Almaden Minerals, Ltd. has 52-Week high of $1.05 and 52-Week Low of $0.48. The stock touched its 52-Week High on 1.05 and 52-Week Low on 0.48. The stock traded with the volume of 0 shares yesterday. The firm shows the market capitalization of $60.19 Million.

The firm is trading with SMA20 of 16 Percent, SMA50 of 10.59 Percent and SMA200 of -12.12 percent. Almaden Minerals, Ltd. has P/S value of 0 while its P/B value stands at 1.25. Similarly, the company has Return on Assets of -5.8 percent, Return on Equity of -6.1 percent and Return on Investment of 0 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 0 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 0 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 2 analysts offering 12-month price forecasts for Almaden Minerals Ltd have a median target of 1.18, with a high estimate of 1.44 and a low estimate of 0.93. The median estimate represents a +93.55% increase from the last price of 0.61.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Cytori Therapeutics Inc. (NASDAQ:CYTX)

Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company’s preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient’s own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.

Cytori Therapeutics Inc. (NASDAQ:CYTX)’s Financial Outlook

The 2 analysts offering 12-month price forecasts for Cytori Therapeutics Inc have a median target of 1.35, with a high estimate of 1.80 and a low estimate of 0.90. The median estimate represents a +307.85% increase from the last price of 0.33.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Cytori Therapeutics Inc. has a Consensus Recommendation of 2. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock surged 0% and closed its last trading session at $0.33. The company has the market capitalization of $4.33 Million. The stock has 52-week high of $5.4 and 52-Week low of $0.29. The firm touched its 52-Week high on 5.40 and 52-Week low on 0.29. The company has volume of 0 shares. The company has a total of 13.07 Million shares outstanding.

Cytori Therapeutics Inc. (NASDAQ) in the last quarter reported its actual EPS of $-0.59/share where the analyst estimated EPS was $-0.45/share. The difference between the actual and Estimated EPS is $-0.14. This shows a surprise factor of -31.1 percent.

The company has YTD performance of -89.03 percent. Beta for Cytori Therapeutics Inc. stands at 2.28 while its ATR (average true range) is 0.03. The company has Weekly Volatility of 9.10%% and Monthly Volatility of 9.26%%.

Cytori Therapeutics Inc. has distance from 20-day Simple Moving Average (SMA20) of -2.62%, Distance from 50-Day Simple Moving Average of -11.35 percent and Distance from 200-Day Simple Moving Average of -78.61%.

The Company currently has ROA (Return on Assets) of -79.5 percent, Return on Equity (ROE) of -261.3 Percent and Return on Investment (ROI) of -77.8% with Gross margin of 59.2 percent and Operating & Profit margin of 0% and 0% respectively.

SHARE